Canada Pension Plan Investment Board Acquires Shares of 5,500 Repligen Co. (NASDAQ:RGEN)

Canada Pension Plan Investment Board purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,500 shares of the biotechnology company's stock, valued at approximately $792,000.

A number of other hedge funds have also recently added to or reduced their stakes in RGEN. Stifel Financial Corp increased its stake in shares of Repligen by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 4,404 shares of the biotechnology company's stock worth $655,000 after purchasing an additional 226 shares during the last quarter. Sanctuary Advisors LLC bought a new position in Repligen during the third quarter valued at about $233,000. Tidal Investments LLC lifted its position in shares of Repligen by 142.8% in the third quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company's stock worth $1,659,000 after buying an additional 6,558 shares during the last quarter. Peapack Gladstone Financial Corp bought a new stake in shares of Repligen during the 3rd quarter worth about $296,000. Finally, Franklin Resources Inc. grew its holdings in Repligen by 8.7% during the third quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company's stock valued at $47,551,000 after purchasing an additional 26,668 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on RGEN. JPMorgan Chase & Co. dropped their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday. Royal Bank of Canada lowered their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday. Canaccord Genuity Group cut their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average target price of $173.25.

Repligen Price Performance

Repligen stock traded down $1.44 during mid-day trading on Wednesday, hitting $137.99. 975,539 shares of the company were exchanged, compared to its average volume of 719,846. The company has a market capitalization of $7.75 billion, a PE ratio of -270.57, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The business has a fifty day moving average of $138.77 and a 200 day moving average of $145.87. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm's quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm posted $0.28 EPS. As a group, sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.